
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is attractive on a risk-adjusted basis because its valuation is supported by a favorable NPV framework while estimates improve to a 2026 EPS loss of $(0.80) from $(0.92), suggesting tighter expected cash burn. Its lead asset, Stenoparib, is advancing in a Phase 2 ovarian cancer trial and a newly announced Phase 2 recurrent SCLC trial that dosed its first patient in February 2026, while the DRP companion diagnostic may improve patient selection and clinical success rates. The investment case is further strengthened by durable efficacy signals, including median overall survival exceeding 25 months and two patients remaining on therapy beyond 29 months as of March 2026, alongside a large PARP market growing from ~$9.0 billion in 2023 toward over $21.0 billion by 2031.
Bears say
Allarity Therapeutics is a clinical-stage company with essentially no revenue, reporting about $0 million in fiscal Q2 2026 and a net loss of $3.4 million, or $(0.21) per share, underscoring its dependence on external financing rather than commercial cash flow. Its lead asset, stenoparib, remains far from de-risked, with long development challenges in advanced recurrent ovarian cancer and uncertainty around safety, efficacy, regulatory approval, and eventual commercialization. The negative outlook is further reinforced by balance sheet and liquidity risks, limited reimbursement prospects, and broad biotech sentiment and macro factors that could impair funding and valuation.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares